Keeping up with the evolution of MS:
Are we using anti-CD20s early enough?
Thursday, 4 December 2025 • 15:30 – 16:30 (UAE Time) Registration starts at 3:00 PM (UAE Time)
Satellite Symposium hosted by Novartis
Al Baraha 1 (Lower Level), Events Centre – InterContinental Dubai Festival City
Al Baraha 1 (Lower Level), Events Centre – InterContinental Dubai Festival City
Program
|
Satellite Symposium hosted by Novartis
Keeping up with the evolution of MS:
Are we using anti-CD20s early enough? Chairperson: Dr. Raed Alroughani (KW) |
||
| 15:30–15:45 |
MS is evolving in the treated era: Are current interventions meeting the challenge? |
Prof. Heinz Wiendl (DE) |
| 15:45–16:00 | What do we need to know about long-term anti-CD20 therapy use and safety? | Prof. Heinz Wiendl (DE) |
| 16:00–16:15 |
Anti-CD20 therapy in family planning: What do we need to know? |
Prof. Kerstin Hellwig (DE) |
| 16:15–16:30 | Q&A |
Prof. Heinz Wiendl & Prof. Kerstin Hellwig |
Faculty
Dr. Raed Alroughani
Consultant Neurologist
Director of MS Clinic at Amiri & Ibn Sina Hospitals
Department of Medicine, Division of Neurology
Director of MS Clinic at Amiri & Ibn Sina Hospitals
Department of Medicine, Division of Neurology
Amiri Hospital, Sharq
Kuwait
Prof. Heinz Wiendl
Professor & Director
Department of Neurology and Neurophysiology
Department of Neurology and Neurophysiology
University Hospital Freiburg
Germany
Prof. Kerstin Hellwig
Senior Consultant Neurologist
and MS Specialist
Department of Neurology
and MS Specialist
Department of Neurology
St. Josef Hospital / Ruhr University Bochum
Germany
Target Audience
- Specialists
- Neurologists
- Practitioners
- Researchers in the field of MS
Registration
Registration is complimentary and can be arranged via the online registration module upon registering for the congress pass.What are the key takeaways from this Symposium?
By attending this symposium you will:
- Explore the importance of early intervention and initiating highly effective therapies (HETs) early in the disease course.
- Facilitate scientific exchange on evolving treatment strategies and their impact on long-term outcomes.
- Review recent clinical and real-world evidence on anti-CD20 therapies in multiple sclerosis.
- Discuss long-term safety and treatment optimization considerations.
- Address practical aspects of family planning in patients receiving anti-CD20 therapy.
Abbreviations: MS: Multiple sclerosis. | Speaker: Prof. Heinz Wiendl, Prof. Heinz Wiendl, Prof. Kerstin Hellwig, Prof. Heinz Wiendl & Prof. Kerstin Hellwig | Duration: 15 min, 15 min, 15 min, 15 min | This symposium is organized and funded by Novartis and is intended within the context of the MENACTRIMS Congress, 2025 in the UAE.
Ref: NOV/2025/FA-11550850